Bausch Health Companies (BHC) Downgraded by ValuEngine to “Sell”

Bausch Health Companies (NYSE:BHC) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

Several other equities research analysts have also recently commented on the company. Wells Fargo & Co set a $9.00 target price on Bausch Health Companies and gave the company a “sell” rating in a research note on Friday, May 17th. JPMorgan Chase & Co. raised Bausch Health Companies from an “underweight” rating to a “neutral” rating and set a $24.80 target price for the company in a research note on Monday, May 13th. Mizuho lifted their target price on Bausch Health Companies from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Cantor Fitzgerald reissued a “buy” rating and issued a $32.00 target price on shares of Bausch Health Companies in a research note on Thursday, April 25th. Finally, Zacks Investment Research raised Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Friday, April 5th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. Bausch Health Companies has an average rating of “Hold” and a consensus target price of $27.99.

NYSE BHC opened at $24.49 on Monday. The firm has a market capitalization of $8.82 billion, a PE ratio of 6.09, a PEG ratio of 0.58 and a beta of 0.55. Bausch Health Companies has a 52 week low of $17.20 and a 52 week high of $28.45. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Monday, May 6th. The company reported $1.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.14. The company had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period last year, the firm earned $0.89 EPS. As a group, equities research analysts expect that Bausch Health Companies will post 4.06 EPS for the current year.

In related news, CEO Joseph C. Papa acquired 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 28th. The stock was acquired at an average cost of $23.67 per share, with a total value of $710,100.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.87% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in the stock. FIL Ltd grew its stake in shares of Bausch Health Companies by 69.6% during the first quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after purchasing an additional 4,327,851 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Bausch Health Companies by 0.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after purchasing an additional 75,175 shares during the period. Bank of Montreal Can grew its stake in shares of Bausch Health Companies by 28.2% during the first quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after purchasing an additional 815,311 shares during the period. Orbimed Advisors LLC grew its stake in Bausch Health Companies by 89.1% in the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after acquiring an additional 1,696,400 shares during the period. Finally, Norges Bank acquired a new position in Bausch Health Companies in the fourth quarter valued at about $59,054,000. 54.70% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Read More: Fibonacci Channel

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.